Frontlight ResearchEarly access
WithdrawnPhase 3
Study Comparing Esomeprazole Associated With Sodium Bicarbonate From Eurofarma and Esomeprazole in Treatment of Gastroesophageal Reflux Disease ESOBIC
Key facts
- Who runs it
- Eurofarma Laboratorios S.A.
- Where
- Brazil6 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Phase
- Phase 3
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Nexium®
- Esomeprazol (40mg) + Sodium Bicarbonate (721mg)
- Record updated
- 1 April 2025
- Why it stopped
- Change company strategy
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- ICF signing
- Age ≥ 18 years
- Gastroesophageal reflux disease diagnosis
- Grade 0 to grade III reflux esophagitis, assessed by means of upper gastrointestinal endoscopy
- Ability to have the endoscopy, pH-metry and esophageal manometry examinations performed
- Washout period of 1 week without using PPI, H2 antagonists and prokinetic agents and of at least 1 day without using antacids
Who cannot take part
- Previous gastric or esophageal surgery
- Concomitant diseases, such as kidney, liver and heart failure
- Abusive drug or alcohol use
- Treatment with PPI, H2 antagonists or prokinetic agents that may not be withheld during the washout period of 1 week or during the study
- Use of nonsteroidal anti-inflammatory drugs (NSAIDs), antiemetic agents, macrolide antibiotics and systemic corticoids for a period equal to or greater than 2 weeks before the study or that is expected to require prolonged use during study treatment
- Concomitant use or requirement of a gastric pH-dependent medication for optimal absorption
- Scheduled use of other medications metabolized by cytochrome CYP during the study
- Suspected or confirmed cancer of any type
- Intolerance or allergy to any of the components in the drug products assessed in the study
- History of active peptic ulcer
- Dietary sodium restriction, metabolic alkalosis, hypokalemia, Barter syndrome; Pregnancy or breastfeeding
- Abnormal values for white blood cells, platelets or hemoglobin
- Significant changes in serum sodium, potassium, calcium or creatinine concentrations
- Rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrose-isomaltase insufficiency
- Presence of esophagitis requiring intervention (grade IV), esophageal varices, Barrett's esophagus, systemic sclerosis or ulcers (gastric or duodenal ulcers)
- Recent participation (within the last 12 months) in another clinical study
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
A phase III, randomized, open-label, superiority study comparing the incremental product esomeprazole associated with sodium bicarbonate made by Eurofarma and Nexium® in the treatment of gastroesophageal reflux disease. The study will enroll 94 patients in each arm (total of 188 patients).
The 2 groups in the trial
- Esomeprazole (40mg) + Sodium Bicarbonate (721mg)Treatment being tested
Treatment: Esomeprazol (40mg) + Sodium Bicarbonate (721mg)
- Nexium®Existing treatment, for comparison
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase III, Randomized, Open-label, Superiority Study Comparing the Incremental Product Esomeprazole Associated With Sodium Bicarbonate Made by Eurofarma and Nexium® in the Treatment of Gastroesophageal Reflux Disease
- Record updated
- 1 April 2025